Kidney Dosimetry in177Lu and90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors

Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy

(2012) Sébastien Baechler et al.   MEDICAL PHYSICS

Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: assuming similar pharmacokinetics,125Sn–177Lu is superior to90Y–177Lu in peptide receptor radiotherapy

(2012) Stephan Walrand et al.   PHYSICS IN MEDICINE AND BIOLOGY

Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy

(2012) Maria Larsson et al.   EJNMMI Research

Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience

(2012) A. Filice et al.   Journal of Oncology

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts

(2011) Stephan Walrand et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Personnel exposure in labelling and administration of 177Lu-DOTA-D-Phe1-Tyr3-octreotide

(2011) Roberto Sghedoni et al.   NUCLEAR MEDICINE COMMUNICATIONS

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy

(2010) Michael Garkavij et al.   CANCER

EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting

(2010) M. Lassmann et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

An evaluation of R2 as an inadequate measure for nonlinear models in pharmacological and biochemical research: a Monte Carlo approach

(2010) Andrej-Nikolai Spiess et al.   BMC Pharmacology & Toxicology

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

(2009) Dik J Kwekkeboom et al.   ENDOCRINE-RELATED CANCER

Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate

(2009) Mattias Sandström et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-patient studies

(2009) Bin He et al.   MEDICAL PHYSICS

Calculation of the biological effective dose for piecewise defined dose-rate fits

(2009) Robert F. Hobbs et al.   MEDICAL PHYSICS

Comparing time activity curves using the Akaike information criterion

(2009) Peter Kletting et al.   PHYSICS IN MEDICINE AND BIOLOGY

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

(2008) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy

(2008) B. W. Wessels et al.   JOURNAL OF NUCLEAR MEDICINE

Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry

(2008) Sébastien Baechler et al.   MEDICAL PHYSICS

Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations

(2008) Elisa Grassi et al.   NUCLEAR MEDICINE COMMUNICATIONS